Study of Transnasal Sphenopalatine Ganglion Block Added to Standard Medication for Headache Relief in Adults with Acute Subarachnoid Hemorrhage

What this Trial Is About

Researchers are studying the use of a transnasal sphenopalatine ganglion SPG block to treat headaches associated with acute subarachnoid hemorrhage aSAH. This randomized controlled pilot study aims to evaluate whether adding the SPG block to standard pain medication reduces headache severity and decreases opioid use during hospitalization and after discharge. The study involves adult patients with secured aneurysms who can communicate their pain scores. Participants are divided into two groups one receiving standard headache care medications and the other receiving the same medications plus the transnasal SPG block. The SPG block is delivered through the nasal passages using a needleless Tx360 device, with medications including 0.75% bupivacaine, sometimes combined with dexamethasone. This intervention is given when specific pain thresholds are met according to the study protocol. During the study, participants pain levels are measured using a numerical pain rating scale from enrollment until discharge from the intensive care unit, up to 14 days. Opioid use is tracked from enrollment until hospital discharge. Safety monitoring is conducted to watch for any adverse effects. Individual participation lasts up to four weeks within the approximately 24-month study timeline.

Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache